Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Drug Profile

Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Alternative Names: Cyrevia; HiCy

Latest Information Update: 11 Sep 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Accentia Biopharmaceuticals; Biovest International
  • Class Antineoplastics; Antirheumatics; Cyclophosphamides; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Autoimmune haemolytic anaemia; Systemic scleroderma

Highest Development Phases

  • Discontinued Multiple sclerosis; Transplant rejection

Most Recent Events

  • 11 Sep 2013 Discontinued - Preclinical for Multiple sclerosis in USA (IV)
  • 11 Sep 2013 Discontinued - Preclinical for Transplant rejection in USA (IV)
  • 14 Sep 2011 Cyrevia™ receives Orphan Drug status for Graft-versus-host disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top